Blood pressure targets and kidney and cardiovascular disease: Same data but discordant guidelines

Bethany Roehm, Daniel E. Weiner

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations

Abstract

Purpose of review Hypertension is highly prevalent in the United States and a major risk factor for the development of cardiovascular disease. Hypertension is common in chronic kidney disease (CKD), and likely contributes to the association between CKD and cardiovascular disease. The ideal systolic BP to reduce cardiovascular disease risk in individuals with CKD is controversial. Recent findings Several societies have released guidelines on the treatment of hypertension in the past year, each differing in important aspects, including BP targets. The release of new guidelines was largely spurred by the results of Systolic Blood Pressure Intervention Trial (SPRINT), which suggested mortality benefit with more intensive BP targets. Recent post-hoc analyses of a subgroup of ACCORD-BP participants suggest a benefit with tighter BP control. However, another post-hoc analysis of ACCORD-BP participants showed worse kidney outcomes with tighter BP control. Summary Lower target BP appears associated with lower mortality in CKD, although longer term benefits with regard to kidney function remain unclear. Within this framework, treatment of hypertension should be tailored to each individual patient, accounting for cardiovascular disease risk, medication tolerance, and individual patient goals.

Original languageEnglish (US)
Pages (from-to)245-250
Number of pages6
JournalCurrent opinion in nephrology and hypertension
Volume28
Issue number3
DOIs
StatePublished - May 1 2019
Externally publishedYes

Keywords

  • Blood pressure
  • Cardiovascular disease
  • Chronic kidney disease
  • Hypertension
  • Systolic blood pressure intervention trial

ASJC Scopus subject areas

  • Internal Medicine
  • Nephrology

Fingerprint

Dive into the research topics of 'Blood pressure targets and kidney and cardiovascular disease: Same data but discordant guidelines'. Together they form a unique fingerprint.

Cite this